Oric Pharmaceuticals Stock Analysis

Oric Stock Analysis Notes

About 93.0% of the company shares are owned by institutional investors. The book value of Oric Pharmaceuticals was now reported as 4.18. The company recorded a loss per share of 1.65. Oric Pharmaceuticals had not issued any dividends in recent years. ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. The company was incorporated in 2014 and is headquartered in South San Francisco, California. Oric Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 83 people. To find out more about Oric Pharmaceuticals contact MD MBA at 650 388 5600 or learn more at https://www.oricpharma.com.

Oric Pharmaceuticals Investment Alerts

Oric Largest EPS Surprises

View All Earnings Estimates

Oric Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Oric Stock Institutional Investors

Note, although Oric Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Oric Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.03 B.

Oric Profitablity

Management Efficiency

Oric Pharmaceuticals has return on total asset (ROA) of (0.2523) % which means that it has lost $0.2523 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3973) %, meaning that it created substantial loss on money invested by shareholders. Oric Pharmaceuticals' management efficiency ratios could be used to measure how well Oric Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of February 6, 2026, Return On Tangible Assets is expected to decline to -0.44. In addition to that, Return On Capital Employed is expected to decline to -0.54. At present, Oric Pharmaceuticals' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 10.8 M, whereas Total Assets are forecasted to decline to about 212.8 M.

Technical Drivers

As of the 6th of February, Oric Pharmaceuticals holds the Variance of 16.1, risk adjusted performance of (0.06), and Coefficient Of Variation of (1,170). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Oric Pharmaceuticals, as well as the relationship between them.

Oric Pharmaceuticals Price Movement Analysis

Oric Pharmaceuticals Insider Trading Activities

Oric Pharmaceuticals Outstanding Bonds

Oric Pharmaceuticals Predictive Daily Indicators

Oric Pharmaceuticals Corporate Filings

Oric Pharmaceuticals Forecast Models

Oric Pharmaceuticals' time-series forecasting models are one of many Oric Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Oric Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Oric Pharmaceuticals Bond Ratings

Oric Pharmaceuticals financial ratings play a critical role in determining how much Oric Pharmaceuticals have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Oric Pharmaceuticals' borrowing costs.

Oric Pharmaceuticals Debt to Cash Allocation

Oric Pharmaceuticals currently holds 3.18 M in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Oric Pharmaceuticals has a current ratio of 18.35, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Oric Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Oric Pharmaceuticals Total Assets Over Time

Oric Pharmaceuticals Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Oric Pharmaceuticals uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Oric Pharmaceuticals Debt Ratio

0.99

It looks as if most of the Oric Pharmaceuticals' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Oric Pharmaceuticals' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Oric Pharmaceuticals, which in turn will lower the firm's financial flexibility.

Oric Pharmaceuticals Corporate Bonds Issued

Oric Net Debt

Stock analysis is the technique used by a trader or investor to examine and evaluate how Oric Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Oric shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Oric Pharmaceuticals. By using and applying Oric Stock analysis, traders can create a robust methodology for identifying Oric entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Oric analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Oric analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Oric Pharmaceuticals stock analysis indicators help investors evaluate how Oric Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Oric Pharmaceuticals shares will generate the highest return on investment. By understating and applying Oric Pharmaceuticals stock analysis, traders can identify Oric Pharmaceuticals position entry and exit signals to maximize returns.

When running Oric Pharmaceuticals' price analysis, check to measure Oric Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oric Pharmaceuticals is operating at the current time. Most of Oric Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oric Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oric Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oric Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.